THE TAPE

PERRIGO COMPANY PLC

$16.18▼ −0.37%
Last close
Relative strength
87RS
of 99, against every stock▲ +2 on the month
Powering up
Unconfirmed
+36.4%
six months against Pharmaceutical Preparations
52-week range
−4.9%
from the high
$9.22$17.02
Setup
squeezeforming
−4.9%
against the pivot at $17.02
No report date on the calendar.
Growth WEAKProof PENDING
Quarter to Sep 26, revenue −5% on a year ago
11/16 O 16.07 H 16.67 L 16.07 Vol 1.6M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS87
vs pivot−4.94%
Tightening—
Dry-up—
Up/down vol0.03
From high5%
forming7 of 7checks
Powering up
Support and resistance
Support below
$15.58
-3.7% · tested 3× · last 14 sessions ago
Resistance above
$16.87
+4.3% · tested 3× · last 5 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 1.6 weeks and fell 10% from its ceiling at its deepest. The pivot is $17.02, and the stock closed 4.9% below it. Its relative strength rating is 87.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-6.9%
Three months against its industry
+44.1%
Six months against its industry
+36.4%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap
11
days
Ex-dividend in 11 days
Nov 27, 2026
  1. Ex-dividendconfirmedin 11d
    Ex-dividend date
    Nov 27, 2026
How it moves on earnings

On average 11.3% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$4.1B
-5.2% year on year
Operating margin
-39.4%
gross 32.3%
Net margin
-43.3%
Free cash flow
$168.2M
7.5% of market cap
Price to sales
0.55×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 26, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 4
Key takeaway
Margins are improving, but the financial turnaround is not yet proven.
Revenue
$988.6M
-3.3% QoQ · -5.2% YoY
Gross margin
32.4%
+1.7 pts QoQ
Net income
−$27.5M
Loss
Free cash flow
$78.7M
Cash generating

What the numbers say

  • Weak: Revenue -5.2% year over year, -3.3% on the quarter
  • Good: Gross margin 32.4%, +1.7 points on the quarter
  • Weak: Net loss $28M
  • Good: Cash generating: operating cash flow $96M, free cash flow $79M
  • Weak: Net debt $2.86B · cash $437M
Revenue by quarter
Free cash flow
Net income
shares +0.4% in a year · net debt $2.9B
Final read
Growth: WEAK · Economic proof: PENDING
Key question: Can the recovery in margins reach operating profit and cash?
The next test is revenue growth: revenue -5.2% year over year, -3.3% on the quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

None of the tracked funds held or sold it in their latest filings.

Flagged by the market sweep
GappedTape · 2026-11-10
+6.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Reported resultsFiling · 2026-11-05
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-11-03
reports 2026-11-04 bmo
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Earnings date movedEvent · 2026-10-22
2026-11-11 -> 2026-11-04
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
GappedTape · 2026-09-26
+5.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-09-25
+6.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-09-25
5.5 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Unusual volumeTape · 2026-09-19
8.3 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders

Nobody bought or sold on the open market in the last 6 months. There were 34 filings for awards, option exercises or shares withheld to pay tax — those happen on a vesting schedule, so they are not a decision to buy or sell.

Most recent filings
2026-09-11 Parker Geoffrey M. · Directoroption exercise1,263$17,253
2026-09-11 Parker Geoffrey M. · Directorwithheld for tax607$8,292
2026-09-11 Alford Bradley A · Directoroption exercise1,263$17,253
2026-09-11 Alford Bradley A · Directorwithheld for tax607$8,292
2026-09-09 Ball David · EVP & CBDOoption exercise7,701$110,432
2026-09-09 Ball David · EVP & CBDOwithheld for tax2,784$39,923
2026-07-08 Winterman Matthew John · EVP, Supply, Ops, Strategyoption exercise15,660$164,743
2026-07-08 Winterman Matthew John · EVP, Supply, Ops, Strategywithheld for tax8,175$86,001

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

The geometry
Level · ceiling$17.02
Wrong below$15.08
Measured target · a squeeze has no height to projectnone
Through to the apex60%
Leaning · and strengtheningup
Length1.6 weeks

Leaning is where price has been sitting against its own range while the range was quiet. It is not a forecast of which way the range opens up, and this site has no measurement that would support one.

What lines up

7 of 7 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
More up-volume than down-volume
Within 15% of its 52-week high

2 checks are not listed because this stock has too little history to judge them — a 200-day average needs 200 sessions. They are left out of the total rather than counted as failures.

What analysts expect
Strong buy0
Buy1
Hold3
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
PERRIGO COMPANY PLC (PRGO) — The Tape